$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

$bcrx Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000117184320003557 Filed on May 11, 2020

Income Statement

Concept	2020 Q2	2020 Q1	2019 Q1
Revenue	$2.871M	$4.823M	$5.887M
YoY Change	98.27%	-18.07%	48.06%
Cost Of Revenue	$0.00	$0.00	$1.399M
YoY Change		-100.0%
Gross Profit	$2.871M	$4.823M	$4.488M
YoY Change	98.27%	7.46%	12.88%
Gross Profit Margin	100.0%	100.0%	76.24%
Selling, General & Admin	$13.88M	$15.87M	$6.238M
YoY Change	60.33%	154.33%	-18.02%
% of Gross Profit	483.56%	328.94%	138.99%
Research & Development	$27.50M	$29.87M	$27.49M
YoY Change	-0.66%	8.63%	49.09%
% of Gross Profit	957.78%	619.26%	612.59%
Depreciation & Amortization	$180.0K	$218.0K	$176.0K
YoY Change	0.0%	23.86%	-5.38%
% of Gross Profit	6.27%	4.52%	3.92%
Operating Expenses	$41.38M	$45.73M	$33.73M
YoY Change	13.87%	35.58%	29.49%
Operating Profit	-$38.51M	-$40.98M	-$29.33M
YoY Change	10.29%	39.71%	32.03%
Interest Expense	$2.918M	$3.047M	$2.726M
YoY Change	-3.86%	11.78%	22.74%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$38.61M	-$37.60M	-$31.05M
YoY Change	2.6%	21.1%	20.44%
Income Tax
% Of Pretax Income
Net Earnings	-$38.61M	-$37.60M	-$31.05M
YoY Change	2.6%	21.08%	20.47%
Net Earnings / Revenue	-1344.72%	-779.58%	-527.5%
Basic Earnings Per Share
Diluted Earnings Per Share	-$239.0K	-$243.9K	-$281.8K
COMMON SHARES
Basic Shares Outstanding	154.3M	154.2M	110.2M
Diluted Shares Outstanding	161.6K	154.2M	110.2M

Balance Sheet

Concept	2020 Q2	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$189.4M	$113.1M	$107.6M
YoY Change	105.54%	5.11%	17.8%
Cash & Equivalents	$173.5M	$101.9M	$34.80M
Short-Term Investments	$15.94M	$11.19M	$72.75M
Other Short-Term Assets	$5.200M	$6.800M	$4.500M
YoY Change	-24.64%	51.11%	-37.5%
Inventory	$5.233M		$600.0K
Prepaid Expenses
Receivables	$3.997M	$5.642M	$5.002M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$203.8M	$125.5M	$117.6M
YoY Change	96.53%	6.68%	12.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.149M	$7.270M	$7.644M
YoY Change	-5.32%	-4.89%	-18.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$11.70M
YoY Change			-71.88%
Other Assets	$3.720M	$3.811M	$5.390M
YoY Change	-14.15%	-29.29%	2327.93%
Total Long-Term Assets	$10.87M	$11.08M	$24.69M
YoY Change	-13.91%	-55.12%	-51.79%
TOTAL ASSETS
Total Short-Term Assets	$203.8M	$125.5M	$117.6M
Total Long-Term Assets	$10.87M	$11.08M	$24.69M
Total Assets	$214.7M	$136.6M	$142.3M
YoY Change	84.54%	-4.04%	-8.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.354M	$10.06M	$6.935M
YoY Change	12.73%	45.08%	93.28%
Accrued Expenses	$24.84M	$20.19M	$16.55M
YoY Change	28.43%	22.03%	5.91%
Deferred Revenue
YoY Change
Short-Term Debt	$29.80M	$29.70M	$29.20M
YoY Change	1.71%	1.71%	1.39%
Long-Term Debt Due	$19.10M	$14.00M	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$102.7M	$92.70M	$66.33M
YoY Change	42.67%	39.76%	-11.97%
LONG-TERM LIABILITIES
Long-Term Debt	$31.70M	$36.50M	$49.60M
YoY Change	-36.35%	-26.41%	178.65%
Other Long-Term Liabilities	$3.800M	$3.700M	$3.889M
YoY Change	1.55%	-4.86%	3789.0%
Total Long-Term Liabilities	$35.50M	$40.20M	$3.889M
YoY Change	848.69%	933.68%	-78.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$102.7M	$92.70M	$66.33M
Total Long-Term Liabilities	$35.50M	$40.20M	$3.889M
Total Liabilities	$138.2M	$132.9M	$70.22M
YoY Change	82.59%	89.28%	-24.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$916.8M	-$878.2M	-$762.8M
YoY Change	14.54%	15.13%	20.94%
Common Stock	$1.764M	$1.542M	$1.103M
YoY Change	59.78%	39.8%	11.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$76.51M	$3.648M	$22.51M
YoY Change
Total Liabilities & Shareholders Equity	$214.7M	$136.6M	$142.3M
YoY Change	84.54%	-4.04%	-8.39%

Cashflow Statement

Concept	2020 Q2	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$38.61M	-$37.60M	-$31.05M
YoY Change	2.6%	21.08%	20.47%
Depreciation, Depletion And Amortization	$180.0K	$218.0K	$176.0K
YoY Change	0.0%	23.86%	-5.38%
Cash From Operating Activities	-$31.04M	-$23.28M	-$27.00M
YoY Change	26.69%	-13.77%	37.37%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	-$120.0K	-$90.00K
YoY Change	-22.22%	33.33%	125.0%
Acquisitions
YoY Change
Other Investing Activities	-$4.860M	$10.84M	$15.97M
YoY Change	-121.73%	-32.12%	0.06%
Cash From Investing Activities	-$4.930M	$10.72M	$15.88M
YoY Change	-122.13%	-32.47%	-0.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	108.2M	$266.0K	20.04M
YoY Change	26287.8%	-98.67%	-1457.72%
NET CHANGE
Cash From Operating Activities	-31.04M	-$23.28M	-27.00M
Cash From Investing Activities	-4.930M	$10.72M	15.88M
Cash From Financing Activities	108.2M	$266.0K	20.04M
Net Change In Cash	72.22M	-$12.29M	8.923M
YoY Change	-4090.06%	-237.75%	-271.53%
FREE CASH FLOW
Cash From Operating Activities	-$31.04M	-$23.28M	-$27.00M
Capital Expenditures	-$70.00K	-$120.0K	-$90.00K
Free Cash Flow	-$30.97M	-$23.16M	-$26.91M
YoY Change	26.87%	-13.93%	37.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q1	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	4000
CY2019Q1	bcrx	Amortization Of Discount And Premium On Investments AmortizationOfDiscountAndPremiumOnInvestments	-62000
CY2020Q1	bcrx	Available For Sale Debt Securities Accrued Interest AvailableForSaleDebtSecuritiesAccruedInterest	103000
CY2019Q4	bcrx	Available For Sale Debt Securities Accrued Interest AvailableForSaleDebtSecuritiesAccruedInterest	116000
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	154253225
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized For Remainder Of Fiscal Year EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedForRemainderOfFiscalYear	6646000
CY2020Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Five EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFive	52000
CY2020Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour	2153000
CY2020Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree	6091000
CY2020Q1	bcrx	Employee Service Share Based Compensation Nonvested Awards Compensation Cost Expected To Be Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo	7273000
CY2017Q4	bcrx	Maximum Aggregate Offering Price MaximumAggregateOfferingPrice	200000000
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000882796
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	BIOCRYST PHARMACEUTICALS INC
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q1	dei	Trading Symbol TradingSymbol	bcrx
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10061000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13988000
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5642000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22146000
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20192000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21365000
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	14000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	39000
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	880319000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	877300000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2754000
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3317000
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2754000
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3317000
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	341000
CY2019Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	255000
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12196000
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3406000
CY2020Q1	us-gaap	Assets Assets	136589000
CY2019Q4	us-gaap	Assets Assets	175282000
CY2020Q1	us-gaap	Assets Current AssetsCurrent	125508000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	164345000
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	15000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	40000
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	11068000
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	21899000
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11185000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22054000
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11185000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	22054000
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101873000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	114172000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	115723000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	28275000
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	103432000
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37198000
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12291000
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8923000
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	154192000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	154082000
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	154192000
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	154082000
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	1542000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1541000
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37624000
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30846000
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1399000
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	45801000
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	35217000
CY2020Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1067000
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2120000
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	218000
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	176000
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	22215000
CY2020Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1301000
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1377000
CY2020Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3729000
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3406000
CY2020Q1	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	-20000
CY2019Q1	us-gaap	Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments	406000
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5100000
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1429000
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1053000
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability
CY2020Q1	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	-20000
CY2019Q1	us-gaap	Increase Decrease In Derivative Assets IncreaseDecreaseInDerivativeAssets	406000
CY2020Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1477000
CY2019Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1544000
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	847000
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1370000
CY2020Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-16504000
CY2019Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	709000
CY2020Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	6446000
CY2019Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	596000
CY2020Q1	us-gaap	Interest Expense InterestExpense	3047000
CY2019Q1	us-gaap	Interest Expense InterestExpense	2726000
CY2020Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	3047000
CY2019Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2726000
CY2020Q1	us-gaap	Interest Payable Current InterestPayableCurrent	16381000
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	14904000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11518000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7903000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	568000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	563000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	582000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	645000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1257000
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6488000
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	136589000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	175282000
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	92699000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	92335000
CY2020Q1	us-gaap	Line Of Credit LineOfCredit	36513000
CY2019Q4	us-gaap	Line Of Credit LineOfCredit	41289000
CY2020Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	14026000
CY2019Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	9020000
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	50000000
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	20000000
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15881000
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23281000
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20040000
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10724000
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	266000
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	563000
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	20000000
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	10000000
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	266000
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26998000
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-37599000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-31054000
CY2020Q1	us-gaap	Notes Payable Current NotesPayableCurrent	29671000
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	29561000
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-40978000
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-29330000
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	448000
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	309000
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.127
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P13Y182D
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3811000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3590000
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-25000
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	208000
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-25000
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	208000
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt
CY2019Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	3018000
CY2020Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	116000
CY2019Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	93000
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5249000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4422000
CY2020Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit
CY2019Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	19477000
CY2020Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	10840000
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	18992000
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7270000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7347000
CY2020Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	5642000
CY2019Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	22146000
CY2020Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0
CY2019Q1	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Before Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax	0
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29867000
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27493000
CY2020Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1559000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1551000
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-878227000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-840628000
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4823000
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5887000
CY2020Q1	us-gaap	Royalty Expense RoyaltyExpense	69000
CY2019Q1	us-gaap	Royalty Expense RoyaltyExpense	87000
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15865000
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6238000
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2754000
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3317000
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	266000
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	220000
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	343000
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	3648000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	38252000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	49235000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	22507000
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; text-indent: 29.7pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 31.9pt; margin: 0pt 0">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of stock options, and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <div style="display: inline; font-style: italic; font: inherit;">not</div> readily apparent from other sources. Actual results could differ from those estimates.</div></div></div>
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	154156000
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	110167000

Files In Submission

Name	View Source	Status
0001171843-20-003557-index-headers.html	Edgar Link	pending
0001171843-20-003557-index.html	Edgar Link	pending
0001171843-20-003557.txt	Edgar Link	pending
0001171843-20-003557-xbrl.zip	Edgar Link	pending
bcrx-20200331.xml	Edgar Link	completed
bcrx-20200331.xsd	Edgar Link	pending
bcrx-20200331_cal.xml	Edgar Link	unprocessable
bcrx-20200331_def.xml	Edgar Link	unprocessable
bcrx-20200331_lab.xml	Edgar Link	unprocessable
bcrx-20200331_pre.xml	Edgar Link	unprocessable
exh_101.htm	Edgar Link	pending
exh_102.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
exh_322.htm	Edgar Link	pending
f10q_050820p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
logo.jpg	Edgar Link	pending
logo2.jpg	Edgar Link	pending
logo3.jpg	Edgar Link	pending
logo4.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2020 Q2 Form 10-Q Financial Statement

#000117184320003557 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX BIOCRYST PHARMACEUTICALS INC Stock $bcrx

2020 Q2 Form 10-Q Financial Statement

#000117184320003557 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BCRX
BIOCRYST PHARMACEUTICALS INC Stock $bcrx